2017 · Tamura — Efficacy of Inhaled Hydrogen on Neurological Outcome Following Brain Ischemia During Post-Cardiac Arrest Care (HYBRID II Trial): Study Protocol for a Randomized Controlled Trial
Super-Abstract
This is the published protocol for the HYBRID II trial — a multicenter, randomized, double-blind, placebo-controlled trial designed to enroll 360 comatose cardiac arrest survivors and evaluate whether 18 hours of 2% hydrogen inhalation improves 90-day neurological outcome. The results appeared in 2023 as HYBRID II: the trial stopped early after 73 patients, and the primary endpoint showed no statistically significant difference. (Trials, 2017.)
Commentary
Brain injury following cardiac arrest is the primary cause of death and long-term disability in survivors. Hydrogen gas inhalation (HI) showed strong neuroprotective effects in animal models of post-cardiac arrest syndrome (PCAS), and a small pilot study confirmed its safety in humans. The HYBRID II protocol represents the logical next step: a properly powered multicenter RCT. The design is rigorous: 360 adult comatose patients (Glasgow Coma Scale < 8) after out-of-hospital cardiac arrest of presumed cardiac cause, randomized 1:1 to either 2% H₂ + 24–50% oxygen or 24–50% oxygen alone for 18 hours, alongside full standard post-arrest care including targeted temperature management (TTM). The primary outcome is the 90-day neurological result on the Cerebral Performance Categories (CPC) scale. The study is powered to detect a 15% absolute improvement in good neurological outcomes (from 50% to 65%) with 80% power. Note: this publication is the trial protocol. The results were published in 2023: HYBRID II.
Key quotes
- „The patients will be randomized (1:1) to either the HI or control group. Patients in the HI group will inhale 2% hydrogen with 24% to 50% oxygen, and those in the control group will inhale 24% to 50% oxygen for 18 h after admission via mechanical ventilation.“ — the trial's intervention: precisely defined H₂ dose and delivery, distinguishing this from vague earlier protocols
- „This study will provide 80% power to detect a 15% change in the proportion of patients with good neurological outcomes (CPCs of 1 and 2), from 50% to 65%, with an overall significance level of 0.05.“ — the power calculation: a meaningful and clinically realistic effect size target
- „Our study has the potential to address HI as an appealing and innovative therapeutic strategy for PCAS in combination with TTM.“ — the clinical positioning: H₂ as a complement to standard targeted temperature management
Our assessment
This publication is a study protocol, not results — its value lies in confirming that a properly powered, well-designed RCT for H₂ in cardiac arrest was initiated. The protocol design is exemplary: multicenter, randomized, double-blinded, pre-registered, adequately powered, clinically meaningful primary outcome. Limitations of the protocol paper: no efficacy data is available from this publication; the feasibility of blinding H₂ vs. oxygen inhalation in an intensive care setting is challenging (though feasible with identical-appearing gas mixtures); 18 hours of H₂ inhalation during mechanical ventilation is logistically complex and limits applicability to well-equipped centers. The trial results are on a separate page: HYBRID II (2023). Enrolment stopped after 73 of the planned 360 patients because of COVID-19.
Study design
- Type: published RCT protocol (not results) · Target n: 360 comatose out-of-hospital cardiac arrest survivors · H₂ delivery: 2% hydrogen inhalation via mechanical ventilation for 18 hours
- Primary outcome: 90-day neurological outcome (Cerebral Performance Categories 1–2 = good) · Registration: UMIN 000019820
- Design features: multicenter, randomized 1:1, double-blind, placebo-controlled; combined with targeted temperature management (TTM 33–36°C); 80% power to detect 15% absolute improvement in good neurological outcome
Abstract
BACKGROUND: Hydrogen gas inhalation (HI) improved survival and neurological outcomes in an animal model of post-cardiac arrest syndrome (PCAS). The feasibility and safety of HI for patients with PCAS was confirmed in a pilot study. The objective of this study is to evaluate the efficacy of HI for patients with PCAS. METHODS/DESIGN: The efficacy of inhaled HYdrogen on neurological outcome following BRain Ischemia During post-cardiac arrest care (HYBRID II) trial is an investigator-initiated, randomized, double-blind, placebo-controlled trial designed to enroll 360 adult comatose (Glasgow Coma Scale score < 8) patients who will be resuscitated following an out-of-hospital cardiac arrest of a presumed cardiac cause. The patients will be randomized (1:1) to either the HI or control group. Patients in the HI group will inhale 2% hydrogen with 24% to 50% oxygen, and those in the control group will inhale 24% to 50% oxygen for 18 h after admission via mechanical ventilation. Multidisciplinary post-arrest care, including targeted temperature management (TTM) between 33 °C and 36 °C, will be provided in accordance with the latest guidelines. The primary outcome of interest is the 90-day neurological outcome, as evaluated using the Cerebral Performance Categories scale (CPC). The secondary outcomes of interest are the 90-day survival rate and other neurological outcomes. This study will provide 80% power to detect a 15% change in the proportion of patients with good neurological outcomes (CPCs of 1 and 2), from 50% to 65%, with an overall significance level of 0.05. DISCUSSION: The first multicenter randomized trial is underway to confirm the efficacy of HI on neurological outcomes in comatose out-of-hospital cardiac arrest survivors. Our study has the potential to address HI as an appealing and innovative therapeutic strategy for PCAS in combination with TTM. TRIALS REGISTRATION: University Hospital Medical Information Network (UMIN), 000019820 . Registered on 17 November 2015.
Source & links
Screenshot of the PubMed page
This page mirrors the published abstract (© the authors / publisher) for reference and citation. The canonical source is the PubMed record linked above. This is not medical advice.